ClinicalTrials.gg
CompletedNCT04541186Updated Jul 25, 2024Results posted

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

A Phase 2 interventional study of Pegozafermin and Placebo in Severe Hypertriglyceridemia, sponsored by 89bio, Inc.. Completed at 48 sites in 4 countries. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by 89bio, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.

Enrollment
54th of 145
86 · median 52
Started
2020
with 4 others
Phase 2
45 of 150
4 open now
Registered
120th of 150
by date

Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 54th largest by enrollment of the 145 interventional ones that give a count, is one of 5 that started in 2020, is one of 45 in phase 2, and was the 120th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertriglyceridemia with a site in United States, or all of them as a file.
02

Study summary

This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly [QW] or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in participants with severe hypertriglyceridemia (SHTG).

03

Conditions studied

  • Severe Hypertriglyceridemia

Keywords

  • Hypertriglyceridemia
  • Dyslipidemia
  • Lipid disorder
  • FGF21
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female age ≥21 to ≤75 years.
  2. Screening fasting triglyceride ≥500 milligrams (mg)/deciliters (dL) and ≤2000 mg/dL.
  3. Willing to maintain current eating and exercise habits from time of signing the and for the duration of the study.
  4. Participants could be taking statins and/or prescription fish oil as background therapy or not be taking any background therapy.
  5. Magnetic resonance imaging - whole liver proton density fat fraction (MRI-PDFF) of ≥6% for participants screened for the Fibrate Expansion cohort.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled or newly diagnosed hypertension.
  2. >45 kilograms (kg)/meters squared (m\^2).
  3. Receiving niacin, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, or supplements that could lower lipid levels.
  4. Type 1 diabetes mellitus.
  5. Diagnosis of Type 2 diabetes mellitus \<6 months prior to screening.
  6. History of within 5 years prior to screening.
  7. Participants with known lipoprotein lipase impairment or deficiency (Fredrickson Type 1), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type 3).
  8. Clinically or otherwise documented cardiovascular or cerebrovascular disease.
  9. Weight change ≥5% in 3 months prior to first screening visit or weight change ≥5% during screening or planning to try to lose weight during conduct of study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Pegozafermin 9 mg QW

    Participants received pegozafermin 9 mg QW as an SC injection for 8 weeks in the Main Study cohort.

    Drug: Pegozafermin

  • Experimental
    Pegozafermin 18 mg QW

    Participants received pegozafermin 18 mg QW as an SC injection for 8 weeks in the Main Study cohort.

    Drug: Pegozafermin

  • Experimental
    Pegozafermin 27 mg QW

    Participants received pegozafermin 27 mg QW as an SC injection for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion pegozafermin 27 mg QW groups were pooled together due to low sample size in the expansion cohort.

    Drug: Pegozafermin

  • Experimental
    Pegozafermin 36 mg Q2W

    Participants received pegozafermin 36 mg Q2W as an SC injection for 8 weeks in the Main Study cohort.

    Drug: Pegozafermin

  • Placebo comparator
    Placebo

    Matching placebo was injected at matching frequency per assigned cohort for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion placebo groups were pooled together due to low sample size in the expansion cohort.

    Drug: Placebo

Interventions

  • Subcutaneous injection

    Also known as: BIO89-100

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Number of Participants Who Achieved TG <500 mg/dL at Week 8

    Time frame: Week 8

  2. Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C)

    Least Squares Means were calculated using mixed-model repeated measures (MMRM).

    Time frame: Baseline, Week 8

  3. Percent Change From Baseline to Week 8 in Very Low-density Lipoprotein Cholesterol (VLDL-C) and VLDL-TG

    Time frame: Baseline, Week 8

  4. Percent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight

    Least Squares Mean was calculated using MMRM.

    Time frame: Baseline, Week 8

  5. Percent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF)

    Least Squares Mean was calculated using analysis of covariance (ANCOVA).

    Time frame: Baseline, Week 8

  6. Percent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP)

    Time frame: Baseline, Week 8

  7. Percent Change From Baseline to Week 8 in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

    Least Squares Mean was calculated using MMRM.

    Time frame: Baseline, Week 8

07

Results

Posted Jul 25, 2024
Limitations and caveats
The study did not separately evaluate the response to pegozafermin in participants who were on and who were not on concurrent fibrate therapy due to small sample size in the Fibrate Expansion cohort.

Participant flow

Main Study
Participant flow — Main Study
MilestonePegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlacebo
Started1617161615
Safety analysis set1221151615
Full analysis set (fas)1617131614
Completed1516101514
Not completed11611
Withdrew: Adverse event00400
Withdrew: Investigator decision00110
Withdrew: Withdrawal by subject11000
Withdrew: Covid-19-related dose interruption00001
Withdrew: Randomized in error not treated00100
Fibrate Expansion Study
Participant flow — Fibrate Expansion Study
MilestonePegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlacebo
Started00303
Received at least 1 dose of study drug00303
Full analysis set00303
Completed00302
Not completed00001
Withdrew: Other than specified00001

Outcome measures

PrimaryPercent Change From Baseline to Week 8 in Serum Triglyceride (TG)
Time frame:
Baseline, Week 8
Reported as:
Median · percent change from Baseline
Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)
percent change from BaselinePegozaferminPlacebo
Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)-57.33 (-69.07 to -32.31)-11.85 (-23.22 to 7.88)
Statistical analysis
  • Pegozafermin vs Placebo · van Elteren test · p = <0.001 (Significant level = 0.05) · Median percent change difference: -43.73 · 95% CI -57.08 to -30.31The location shift and Hodges-Lehmann 95% confidence interval were based on Hodges-Lehman estimation. Placebo group is the reference group, and the comparison was performed in pooled pegozafermin treatment group vs. placebo pooled.
SecondaryNumber of Participants Who Achieved TG <500 mg/dL at Week 8
Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Who Achieved TG <500 mg/dL at Week 8
ParticipantsPegozaferminPlacebo
Number of Participants Who Achieved TG <500 mg/dL at Week 8515
Statistical analysis
  • Pegozafermin vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 (Significant level = 0.05)Cochran-Mantel-Haenszel test stratified by baseline TG level and lipid modifying therapy use.
SecondaryPercent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C)

Least Squares Means were calculated using mixed-model repeated measures (MMRM).

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change from Baseline
Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C)
percent change from BaselinePegozaferminPlacebo
Non-HDL-C-18.29 ± 2.943-0.57 ± 5.586
ApoB-10.51 ± 2.2381.07 ± 4.309
LDL-C10.44 ± 4.6548.72 ± 9.018
HDL-C24.65 ± 3.7529.67 ± 7.045
Statistical analysis
  • Pegozafermin vs Placebo · MMRM · p = 0.007 (Significant level = 0.05) · Least squares means difference: -17.87 · 95% CI -30.67 to -5.07
  • Pegozafermin vs Placebo · MMRM · p = 0.019 (Significant level of 0.05) · Least squares means difference: -11.75 · 95% CI -21.48 to -2.01
  • Pegozafermin vs Placebo · MMRM · p = 0.870 (Significant level = 0.05) · Least squares means difference: 1.73 · 95% CI -19.21 to 22.68
  • Pegozafermin vs Placebo · MMRM · p = 0.064 (Significant level = 0.05) · Least squares means difference: 15.41 · 95% CI -0.89 to 31.70
SecondaryPercent Change From Baseline to Week 8 in Very Low-density Lipoprotein Cholesterol (VLDL-C) and VLDL-TG
Time frame:
Baseline, Week 8
Reported as:
Median · percent change from Baseline
Percent Change From Baseline to Week 8 in Very Low-density Lipoprotein Cholesterol (VLDL-C) and VLDL-TG
percent change from BaselinePegozaferminPlacebo
VLDL-C-47.96 (-63.14 to -16.67)-0.41 (-30.38 to 10.98)
VLDL-TG-58.50 (-72.53 to -32.80)-0.85 (-27.72 to 14.25)
Statistical analysis
  • Pegozafermin vs Placebo · van Elteren Test · p = 0.006 (Significant level = 0.05)
  • Pegozafermin vs Placebo · van Elteren test · p = 0.002 (Significant level of 0.05)
SecondaryPercent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight

Least Squares Mean was calculated using MMRM.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change from Baseline
Percent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight
percent change from BaselinePegozaferminPlacebo
Fasting Plasma Glucose-3.90 ± 2.681-2.67 ± 5.230
Adiponectin69.53 ± 7.3835.70 ± 14.556
Body Weight-0.15 ± 0.339-0.14 ± 0.654
Statistical analysis
  • Pegozafermin vs Placebo · MMRM · p = 0.809 (Significant level = 0.05)
  • Pegozafermin vs Placebo · MMRM · p = <0.001 (Significant level = 0.05)
  • Pegozafermin vs Placebo · MMRM · p = 0.973 (Significant level = 0.05)
SecondaryPercent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF)

Least Squares Mean was calculated using analysis of covariance (ANCOVA).

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change from Baseline
Percent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF)
percent change from BaselinePegozaferminPlacebo
Percent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF)-42.18 ± 6.207-8.26 ± 11.214
Statistical analysis
  • Pegozafermin vs Placebo · ANCOVA · p = 0.012 (Significant level = 0.05)
SecondaryPercent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP)
Time frame:
Baseline, Week 8
Reported as:
Median · percent change from Baseline
Percent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP)
percent change from BaselinePegozaferminPlacebo
Percent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP)-21.43 (-43.30 to 42.37)-1.10 (-50.41 to 18.84)
SecondaryPercent Change From Baseline to Week 8 in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

Least Squares Mean was calculated using MMRM.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · percent change from Baseline
Percent Change From Baseline to Week 8 in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
percent change from BaselinePegozaferminPlacebo
ALT-4.28 ± 4.5490.43 ± 8.881
AST-11.50 ± 3.3410.51 ± 6.597

Adverse events

Collected over Day 1 (after dosing) up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegozafermin 9 mg QW0/12 (0%)0/12 (0%)7/12 (58.3%)
Pegozafermin 18 mg QW0/21 (0%)0/21 (0%)13/21 (61.9%)
Pegozafermin 27 mg QW0/18 (0%)1/18 (5.6%)13/18 (72.2%)
Pegozafermin 36 mg Q2W0/16 (0%)0/16 (0%)7/16 (43.8%)
Placebo0/18 (0%)0/18 (0%)9/18 (50%)
Most frequent serious events
Most frequent serious events
EventPegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlacebo
HypertensionVascular disorders0/120/211/180/160/18
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlacebo
NauseaGastrointestinal disorders1/121/215/182/160/18
DiarrhoeaGastrointestinal disorders2/121/214/180/161/18
COVID-19Infections and infestations0/123/210/181/163/18
Injection site reactionGeneral disorders1/122/211/182/160/18
Injection site erythemaGeneral disorders0/121/212/181/160/18
Abdominal painGastrointestinal disorders0/120/212/181/160/18
FatigueGeneral disorders0/120/211/180/162/18
Back painMusculoskeletal and connective tissue disorders0/120/212/180/160/18
HeadacheNervous system disorders0/120/210/180/162/18
Injection site pruritusGeneral disorders1/122/211/180/160/18

Baseline characteristics

Safety Analysis Set: All participants who received at least 1 dose of study drug. Participants are summarized by treatment received. As per SAP, since a low number of participants enrolled in the fibrate cohort, participants randomized to pegozafermin 27 mg QW fibrate cohort were combined with the pegozafermin 27 mg QW main cohort, forming a pooled pegozafermin 27 mg QW group for analyses. Similarly, the placebo participants in the fibrate cohort were combined with the main placebo group.

Age, Continuous
Age, Continuous(years)Pegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlaceboTotal
Mean52.8 ± 14.1251.3 ± 10.8153.9 ± 7.1853.1 ± 12.3657.5 ± 10.3053.7 ± 10.86
Sex: Female, Male
Sex: Female, Male(Participants)Pegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlaceboTotal
Female4452621
Male81713141264
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlaceboTotal
Hispanic or Latino3245317
Not Hispanic or Latino91914111568
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlaceboTotal
Race — Black100012
Race — White112118141781
Race — Not Reported000101
Race — Unknown000101
Triglyceride (TG) Level
Triglyceride (TG) Level(Participants)Pegozafermin 9 mg QWPegozafermin 18 mg QWPegozafermin 27 mg QWPegozafermin 36 mg Q2WPlaceboTotal
<750 mg/dL9141291357
≥750 mg/dL3767528
08

Study locations

48 sites
  • 89Bio Clinical Study Site
    La Mesa, California 91942, United States
  • 89Bio Clinical Study Site
    San Francisco, California 94158, United States
  • 89Bio Clinical Study Site
    Clearwater, Florida 33756, United States
  • 89Bio Clinical Study Site
    Greenacres City, Florida 33467, United States
  • 89Bio Clinical Study Site
    Jacksonville, Florida 32205, United States
  • 89Bio Clinical Study Site
    Miami Lakes, Florida 33014, United States
  • 89Bio Clinical Study Site
    Miami Lakes, Florida 33016, United States
  • 89Bio Clinical Study Site
    Miami, Florida 33125, United States
  • 89Bio Clinical Study Site
    Miami, Florida 33135, United States
  • 89Bio Clinical Study Site
    North Miami Beach, Florida 33162, United States
  • 89Bio Clinical Study Site
    Orlando, Florida 32825, United States
  • 89Bio Clinical Study Site
    Tampa, Florida 33606, United States
  • 89Bio Clinical Study Site
    Lawrenceville, Georgia 30044, United States
  • 89Bio Clinical Study Site
    Quincy, Illinois 62301, United States
  • 89Bio Clinical Study Site
    Wauconda, Illinois 60084, United States
  • 89Bio Clinical Study Site
    West Des Moines, Iowa 50266, United States
  • 89Bio Clinical Study Site
    Louisville, Kentucky 40213, United States
  • 89Bio Clinical Study Site
    Olive Branch, Mississippi 38654, United States
  • 89Bio Clinical Study Site
    Albany, New York 12203, United States
  • 89Bio Clinical Study Site
    Greensboro, North Carolina 27408, United States
  • 89Bio Clinical Study Site
    Morganton, North Carolina 28655, United States
  • 89Bio Clinical Study Site
    Marion, Ohio 43303, United States
  • 89Bio Clinical Study Site
    Summerville, South Carolina 29435, United States
  • 89Bio Clinical Study Site
    Chattanooga, Tennessee 37421, United States
  • 89Bio Clinical Study Site
    Kingsport, Tennessee 37660, United States
  • 89Bio Clinical Study Site
    Austin, Texas 78705, United States
  • 89Bio Clinical Study Site
    Dallas, Texas 75204, United States
  • 89Bio Clinical Study Site
    Dallas, Texas 77365, United States
  • 89Bio Clinical Study Site
    Houston, Texas 77089, United States
  • 89Bio Clinical Study Site
    Lampasas, Texas 76550, United States
  • 89Bio Clinical Study Site
    Magnolia, Texas 77355, United States
  • 89Bio Clinical Study Site
    Manassas, Virginia 20110, United States
  • 89Bio Clinical Study Site
    Pardubice, 530 02, Czechia
  • 89Bio Clinical Study Site
    Prague, 100 00, Czechia
  • 89Bio Clinical Study Site
    Prague, 150 00, Czechia
  • 89Bio Clinical Study Site
    Prague, 158 00, Czechia
  • 89Bio Clinical Study Site
    Praha 4, 14021, Czechia
  • 89Bio Clinical Study Site
    Miskolc, Borsod-Abauj-Zemplen 3529, Hungary
  • 89Bio Clinical Study Site
    Baja, Hungary
  • 89Bio Clinical Study Site
    Budapest, 1032, Hungary
  • 89Bio Clinical Study Site
    Békéscsaba, 5600, Hungary
  • 89Bio Clinical Study Site
    Debrecen, 4032, Hungary
  • 89Bio Clinical Study Site
    Białystok, 15-351, Poland
  • 89Bio Clinical Study Site
    Białystok, 15-879, Poland
  • 89Bio Clinical Study Site
    Lodz, 93-338, Poland
  • 89Bio Clinical Study Site
    Oswiecim, 32-600, Poland
  • 89Bio Clinical Study Site
    Rzeszów, 35-055, Poland
  • 89Bio Clinical Study Site
    Toruń, 87-100, Poland
09

References and documents

Publications

  • Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP; ENTRIGUE Principal Investigators. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med. 2023 Jul;29(7):1782-1792. doi: 10.1038/s41591-023-02427-z. Epub 2023 Jun 24. Erratum In: Nat Med. 2024 Jun;30(6):1788-1789. doi: 10.1038/s41591-024-02890-2. PubMed 37355760 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in May 2022, 20 months.

Results were first posted in Jul 2024, 2 years 2 months after primary completion.

Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Sep 9, 2020
StartActual
Sep 1, 2020
Primary completionActual
May 19, 2022
CompletionActual
May 31, 2022
Results first posted
Jul 25, 2024
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04541186
Lead sponsor
89bio, Inc.
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Sep 1, 2020
Primary completion
May 19, 2022
Completion
May 31, 2022
Results posted
Jul 25, 2024
Last update
Jul 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegozafermin

Start the discussion